Supported by

TAVI (Transcatheter aortic valve implantation)

Find all the latest content on TAVI published on this website.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Find out more…

Filtered By

662 results

TAVI: Parallel suture technique in vivo

The aim of this study published in EuroIntervention was to evaluate vascular complications using the “parallel suture technique” in patients receiving an Edwards SAPIEN XT (SXT) or SAPIEN S3 (S3) transcatheter heart valve (THV).

First in human implantation of a novel transfemoral self-expanding transcatheter heart valve to treat pure aortic regurgitation

The first case of a novel JenaValve design using the transfemoral approach in a 78 year old female patient with pure aortic regurgitation is described in this article.

Authors :

Ulrich Schaefer, Johannes Schirmer, Schofer Niklas, Eva Harmel, Florian Deuschl and Lenard Conradi

First FIM Percutaneously Implanted Heart Valve (PHV) implantation on 16 April, 2002

On April 16, 2002, at the Charles Nicolle University Hospital in Rouen, France, the Interventional Cardiologist, Professor Alain Cribier performed the first transcatheter aortic valve replacement procedure in the world. He used a Prosthetic valve thrombosis (PVT) percutaneous heart valve.

Prof. Alain Cribier


Alain Cribier

SPOTLIGHT: Standardised definitions for clinical and imaging endpoints after surgical and transcatheter valve intervention

In this presentation from PCR London Valves 2017, A. Baumbach, D. Capodanno, A. Lansky, M.B. Leon and N. Piazza focus on the durability, structural deterioration and valve failure, the neurological adverse events and on what really matters in clinical and patient-reported endpoints after surgical and transcatheter valve interventions.

Emergency left main PCI with ‘chimney technique’ to treat coronary artery occlusion after valve-in-valve TAVI

A 77 y/o gentleman with previous aortic valve replacement was referred to our unit to undergo valve-in-valve TAVI for symptomatic bioprosthesis degeneration. His surgical risk was deemed prohibitive due to an infiltrating bowel carcinoma awaiting for surgery…

Going beyond boundaries in structural heart interventions?

25 Sep 2017 - From PCR LONDON VALVES 2017

Chairpersons: M.B. Leon, F. Maisano, A. Vahanian

Objectives: To gain perspective from thought leaders on how the cathlab will evolve over the next 5-10 years, to participate to a unique discussion on the evolution of structural heart interventions, to learn the preferred strategy for combined cardiac diseases: while a staged approach may represent a preferable strategy in selected patients, concomitant treatment of combined cardiac diseases represents an appealing option in a majority of patients.

TAVI in difficult anatomy

26 Sep 2017 – From PCR London Valves 2017

Consult a selection of 6 cases to learn how to perform TAVI in difficult anatomy, in particular:
- Left ventricular outflow tract decalcification prior to TAVI: a simple way to prevent paravalvular leakage and mechanical complications
- Is contrast-enhanced CT necessary for emergent balloon aortic valvuloplasty
- Riding through twisty roads: Evolut R crossing a severely tortuous and calcified aorta

A new era in TAVI: key recommendations from the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease

17 Oct 2017 - From PCR LONDON VALVES 2017

Bernard Prendergast, UK, shares key recommendations from the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease, amongst them the continued endorsement of the practice of the Heart Team, new international randomised controlled trials demonstrating the effectiveness of TAVI in intermediate-risk patients, and long-term follow-up of these patients to be shared by all members of the Heart Team.

TAVI is now a mature technology that will become the dominant treatment for aortic stenosis in the very near future, and will require a change in the patient referral pathway from cardiac surgeon to cardiologist. It will also pose a challenge: as the number of patients eligible for TAVI is set to triple to quadruple within the next 5 years, programmes already saturated in many centres will be under pressure, and extended training will be needed for the next generation of interventional cardiologists.

Learnings from the SAVI-TF registry and the MORENA comparative analysis

16 Oct 2017 - From PCR LONDON VALVES 2017

Won-Keun KIM, Germany, discusses two studies on devices that can be used in all patients that physicians encounter. The SAVI-TF registry is a post-market registry performed after CE-mark in order to look at the safety and efficacy of the self-expanding ACURATE-neo™ transcathether valve. An all-comers registry displaying real life procedures, it looked at a contemporary TAVI population of 1,000 patients. Outcome data were excellent: outstanding 30-day mortality of 1.4% and moderate to severe PV leaks at around 4%.

The MORENA study is a multicenter propensity-matched comparison of two novel transfemoral transcathether heart valves : ACURATE neo™ vs SAPIEN™ 3, considered as the standard for TAVI treatment today. A retrospective analysis was performed in 3 centres in German. Procedure outcomes showed no difference between the two devices, except for some minor differences regarding PVL where the SAPIEN™3 performed slightly better, but the ACURATE-neo™ had some other advantages with pacemaker rate and post-procedure gradients.

Perspectives from the REPRISE III randomised trial

16 Oct 2017 - From PCR LONDON VALVES 2017

Lars Sondergaard, Denmark talks about the REPRISE III trial, presented at EuroPCR 2017. A prospective, randomised investigation of a novel transcathether aortic valve implantation system, the trial compares the Lotus valve and the CoreValve, with findings that show the far better performance of the Lotus valve in minimising paravalvular leak (PVL).
As the only mechanical expandable valve with an adaptive sealing, the Lotus valve allows for result assessment before the valve is deployed, letting the physician reposition it as needed, which makes it unique on the market.